Heron Therapeutics (HRTX) Cut to “Sell” at BidaskClub

Share on StockTwits

BidaskClub cut shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a sell rating in a report issued on Monday.

A number of other equities research analysts have also recently weighed in on HRTX. Cantor Fitzgerald set a $50.00 price target on shares of Heron Therapeutics and gave the company a buy rating in a research report on Tuesday, October 30th. Zacks Investment Research cut shares of Heron Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 13th. ValuEngine raised shares of Heron Therapeutics from a sell rating to a hold rating in a research report on Wednesday, January 2nd. Finally, Needham & Company LLC reissued a buy rating and issued a $64.00 price target (down from $66.00) on shares of Heron Therapeutics in a research report on Wednesday, January 16th. Two analysts have rated the stock with a sell rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $51.91.

Shares of HRTX opened at $26.31 on Monday. Heron Therapeutics has a 1-year low of $20.05 and a 1-year high of $42.90. The firm has a market capitalization of $2.19 billion, a P/E ratio of 7.21 and a beta of 1.64.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cohen Capital Management Inc. increased its stake in Heron Therapeutics by 0.6% in the fourth quarter. Cohen Capital Management Inc. now owns 141,780 shares of the biotechnology company’s stock valued at $3,678,000 after purchasing an additional 780 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Heron Therapeutics by 24.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 929 shares during the period. Jennison Associates LLC increased its stake in Heron Therapeutics by 0.9% in the third quarter. Jennison Associates LLC now owns 227,051 shares of the biotechnology company’s stock valued at $7,186,000 after purchasing an additional 2,051 shares during the period. Boston Advisors LLC increased its stake in Heron Therapeutics by 11.7% in the fourth quarter. Boston Advisors LLC now owns 24,740 shares of the biotechnology company’s stock valued at $642,000 after purchasing an additional 2,595 shares during the period. Finally, Private Asset Management Inc. increased its stake in Heron Therapeutics by 2.9% in the fourth quarter. Private Asset Management Inc. now owns 93,882 shares of the biotechnology company’s stock valued at $2,435,000 after purchasing an additional 2,625 shares during the period.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Options Trading – What is a Straddle?

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply